Expression and prognostic value of FAS receptor/FAS ligand and TrailR1/TrailR2 in acute myeloid leukemia

Hematology

Volumn 16, Issue 6, 2011, Pages 341-350

  Pordzik, Sandra ^a   Petrovici, Karin ^a   Schmid, Christoph ^b   Kroell, Tanja ^a   Schweiger, Cornelia ^c   Köhne, Claus Henning ^c   Schmetzer, Helga ^a,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Municipal Hospital Augsburg   (Germany)

^c KLINIKUM OLDENBURG   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

AML; Apoptosis; FasR; Immune escape; Prognosis; TrailR

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS LIGAND; FAS RECEPTOR; RECEPTOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; T LYMPHOCYTE; TREATMENT OUTCOME; UPREGULATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIGENS, CD95; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PROGNOSIS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; T-LYMPHOCYTES; YOUNG ADULT;

EID: 82955223355     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453311X13127324303353     Document Type: Article

References (43)

1. Krammer PH, Dhein J, Walczak JH, Behrmann I, Mariani S, Matiba B, et al. The role of APO-1-mediated apoptosis in the immune system. Immunol Rev 1994;142:175-91.
2. Josien R, Müschen M, Gilbert E, Douillard P, Heslan JM, Soulillou JP, Cuturi MC. Fas ligand, tumor necrosis factoralpha expression, and apoptosis during allograft rejection and tolerance. Transplantation 1998;66(7):887-93.
3. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-3.
4. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin DK. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277(5327):818-21.
5. Walczak H, Degli-Eposti HA, Johnson RS, Smolak PJ, Waugh YJ, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16:5386-97.
6. Screaton GR, Mongkolsapaya N, Xu JX, Cowper AE, McMichael AJ, Bell JI. TRICK 2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997;7:693-6.
7. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997;7(6):821-30.
8. Schneider P, Tschopp J. Modulation of death receptor signalling. Symp Soc Exp Biol 2000;52:31-42.
9. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes- Alnemri T, Cohen GE, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997;272:25417-20.
10. Degli-Eposti MA, Dougall MC, Smolka PJ, Waugh YJ, Smith CA, Goodwin RG. The novel receptor Trail-R4 induces NF-B and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813-20.
11. Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol 1996;6:750-2.
12. Delia D, Accomero P, Redrizzani M, Gerosa F, Kurrle R, Colombo MP. Differential susceptibility to HIV-GP120-sensilized apoptosis in CD4z-T-cell clones with different T helper phenotypes: role of CD95/CD95L interactions. Blood 1997;89(2):558-69.
13. Traver D, Akashi K, Weismann IL, Lagasse E. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukaemia. Immunity 1998;9(1):47-57.
14. Gores G, Chen XJ, Paya CV, la Russo NF. Cryptosporidium parvum induced apoptosis in biliary epithelia by a Fas-Fasligand- dependent mechanism. Am J Physiol 1999;277(3Pt1): G599-608.
15. Rieux-Laucat F, Fischer A, Deist FL. Cell-death signalling and human disease. Curr Opin Immunol 2003;15(3):325-31.
16. Buzyn A, Petit F, Ostankovitch M, Figueiredo S, Varet B, Guillet JG, et al. Mambran-Bound Fas (Apo-1/CD95) Ligand on leukemic cells: a mechanism of tumor immune escape in leukemia patients. Blood 1999;94(9):3135-40.
17. Bennett JM, Catovsky D, Daniel MT. Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative Group. Br J Haematol 1976;33:451-8.
18. Mrozek K, Heinonen K, de la Chapette A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997;24:17-31.
19. Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003;102:2395-420.
20. Rothe G, Schmitz G. (working group on flow cytometry and image analyses). Consensus protocol for the flow cytometric immunophenotying of hematopoietic malignancies. Leukemia 1996;10:877-95.
21. Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K, Schmetzer H. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol 2004;72(2):89-106.
22. Iijima N, Miyamura K, Itou T, Tanimoto M, Sobue R, Saito H. Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: possible correlation with sensitivity of chemotherapy. Blood 1997;90(12): 4901-9.
23. Almodovar R, Zarco P, Quiros FJ, Mazzucchelli R. Infliximab treatment efficacy in lymphoedema associated with ankylosing spondylitis. Rheumatol 2004;43(11):1456.
24. Shipmann CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo 2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003;63(5):912-6.
25. Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D, et al. Trail decoy receptors mediate resistance to acute myeloid leukemia cells to TRAIL. Haematologica 2005;90(5):612-24.
26. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, et al. Inhibitors of histone deacetylases induce tumorselective apoptosis through activation of the death receptor pathway. Nat Med 2005;11(1):71-6.
27. Xue C, Lan-Lan W, Bei C, Jie C, Wei-Hua F. Abnormal Fas/ FasL and caspase-3-mediated apoptotic signaling pathways of T lymphcyte subsets in patients with systemic lupus erythematosus. Cell Immunol 2006;239(2):121-8.
28. Lickliter JD, Kratzke RA, Nguyen PL, Niehans GA, Miller JS. Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis. Exp Hematol 1999;27(10):1519-27.
29. Lee IJ, Chung IJ, Park MR, Ryang DW, Park CS, Kim HJ. Increased angiogenesis and Fas-ligand expression are independent processes in acute myeloid leukaemia, Leuk Res 2001;25(12):1067-73.
30. Min YJ, Lee HJ, Choi SJ, Chi HS, Lee JS, Kim WK, et al. Prognostic significance of Fas(Cd95) and TRAIL receptors (DR4/DR5) expression in acute myelogenous leukaemia. Leuk Res 2004;28(4):39-65.
31. Lewis NR, Pallis M, Russel NH. Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukemis. Exp Hematol 2000;28(5):535-42.
32. Iwai K, Miyawaki T, Takizawa T, Konno A, Ohta K, Yachie A, et al. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in periphl blood lymphocytes, monocytes and neutrophils. Blood 1994;84(4):1201-8.
33. Zhao S, Wang HX, Mao H, Xiao J, Zou P. Expression and its significance of TRAIL and its receptors in cells of patients with acute myeloid leukaemia. Zhongguo Shi Yan Xue Za Zhi 2005;13(1):65-9.
34. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Ofao A, et al. Proposal for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9(10):1783-6.
35. Findley HW, Zhou M. The clinical significance of Fas expression in leukemia; questions and controversies. Leukemia 1999;13(2):147-9.
36. Kelley S, Ashkenazi A. Targeting death receptors in cancer with Apo-2L/TRAIL. Curr Opin Pharmacol 2004;4(4):333-9.
37. Johnston JB, Karborl AF, Strutinsky J, Hu X, Paul JT, Kropp DM. Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphcytic leukemia. Oncogene 2003;22(51):8356-69.
38. Insinga A, Minucci S, Palicci PG. Mechanisms of selective anticancer action of histone deacetylase inhibitors. Cell Cycle 2005;4:741-3.
39. Selleri C, Maciejewski JP, Pane F, Luciano L, Raiola AM, Mostarda I. Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis. Blood 1998;92(3):981-9.
40. Kasibhatla S, Genstier L, Green DR. Regulation of fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor kappa B. J Biol Chem 1999;274(2):987-92.
41. Morales J, Magana MJ, Ruiz-Ruiz C. Regulation of the resitance to Trail-induced apoptosis in human primary T lymphocytes: role of NF-kB inhibition. Mol Immunol 2007;44(10):2587-97.
42. Dorothee G, Vergnon I, Menez J, Echchakir H, Grunenwald D, Kubin M. Tumor-infiltrating CD4z T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with antologous lung carcinoma cells: role of IFN-alpha on APO2L/ TRAIL expression and-mediated cytotoxity. J Immunol 2002;169(2):809-17.
43. Hasegawa H, Yamada Y, Harasawa H, Tsuji T, Murata K, Sugahara K. Restricted expression of tumor necrosis factorrelated apoptosis-inducing ligand receptor 4 in human peripheral blood lymphocytes. Cell Immunol 2004;231(1-2):1-7.